ORTHO MICRONOR Rx
Generic Name and Formulations:
Norethindrone 0.35mg (28 tabs).
Janssen Pharmaceuticals, Inc.
Indications for ORTHO MICRONOR:
Continuous regimen: 1 tab daily.
Premenarchal: not recommended.
Known or suspected breast carcinoma. Undiagnosed abnormal genital bleeding. Liver tumors. Acute liver disease. Pregnancy (Cat.X).
Cigarette smoking. Ectopic pregnancy (monitor). Increased risk of breast cancer. Do physical exams at least annually. Monitor carbohydrate and lipid metabolism. Discontinue if migraine or other serious headaches occur. Use back-up contraception for 48hrs if taken 3hrs or more late. Nursing mothers: if not exclusively breastfeeding may start 3 weeks after delivery; if fully breastfeeding may start 6 weeks after delivery.
Antagonized by hepatic enzyme-inducing drugs (eg, phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort, bosentan). May affect lab tests (eg, sex hormone binding globulins, thyroid).
Menstrual irregularities, frequent or irregular bleeding, headache, breast tenderness, nausea, dizziness; delayed follicular atresia, ovarian cysts, androgenic effects (rare).
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness